Stoke Therapeutics, Inc.
zorevunersen
Dravet syndrome
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews zorevunersen for Dravet syndrome around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 8-K
verified 13h ago
“The FDA has requested additional information, and discussions between the Company and the FDA are ongoing regarding potential opportunities to expedite the development, registration and delivery of zorevunersen to patients.”